Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS

Inclusion Criteria: 1. Patients must be diagnosed with acute myeloid leukemia (non-acute promyelocytic leukemia)/high-risk myelodysplastic syndrome before admission. Diagnostic criteria refer to 2016 WHO classification. 2. Age 60 or older. 3. The scores of physical fitness in the Eastern Tumor Cooperative group (ECOG) ranged from 0 to 3(see Appendix 1). 4. Creatinine clearance ≥30 mL/min(as assessed by the Cockcrod-Gault formula \[Cockcroft et al 1976\] \[13\] or the estimated glomerular filtration rate \[eGFR\] from the Kidney Drink adjustment formula . 5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)≤3× upper limit of normal range (ULN), total bilirubin ≤2×ULN. 6. Echocardiography (ECHO) showed left ventricular ejection fraction (LVEF)≥50% (AHA 2016). 7. Life expectancy \>8 weeks. 8. Sign the informed consent voluntarily, and understand and comply with the requirements of the study. Exclusion Criteria: 1. Age \<60 years old. 2. Treated patients who had received various chemotherapy regiments. 3. Present clinically significant active cardiovascular disease, such as uncontrolled arrhythmia, uncontrolled hypertension, congestive heart failure, any grade 3 or 4 heart disease as determined by the New York Heart Association (NYHA) functional scale (see Appendix 2), or history of myocardial infarction in the 6 months prior to screening. 4. Other serious diseases that may limit participation in the trial (e.g. advanced infections, uncontrolled diabetes). 5. Those who cannot understand and follow the research plan or sign the informed consent.